Get the Stockscreener App
2.45
5.22%
-0.135
After Hours:
2.44
-0.01
-0.41%
Evaxion A S Adr stock is traded at $2.45, with a volume of 47,540.
It is down -5.22% in the last 24 hours and up +3.81% over the past month.
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
See More
Previous Close:
$2.585
Open:
$2.61
24h Volume:
47,540
Relative Volume:
0.53
Market Cap:
$19.08M
Revenue:
-
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.175
EPS:
-14
Net Cash Flow:
$-24.56M
1W Performance:
+5.60%
1M Performance:
+3.81%
6M Performance:
-53.77%
1Y Performance:
-82.93%
1-Day Range:
$2.43
$2.6931
1-Week Range:
$2.25
$2.95
52-Week Range:
$1.20
$17.75
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
2.45 | 19.08M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - GlobeNewswire Inc.
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Evaxion secures Nasdaq listing with equity boost - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
After A Decline Of -818.6% From The High, Can Evaxion Biotech A/S ADR (NASDAQ: EVAX) Recover Quickly? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
Evaxion Biotech A/S ADR (EVAX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Palantir Technologies Surges 16.5% in Pre-Market Trading After Strong Q4 Earnings Report - HPBL
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Argo Blockchain Plc ADR (ARBK)’s stock price in review: A technical analysis - US Post News
Evaxion Biotech A/S ADR (EVAX)’s stock decline to 2.40 per share - US Post News
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
In the Green: Evaxion Biotech A/S ADR (EVAX) Closes at 2.40, Up/Down -2.24 from Previous Day - The Dwinnex
Market Insights: Kairos Pharma Ltd (KAPA)’s Notable Gain of 6.29, Closing at 1.52 - The Dwinnex
Palantir Technologies at a Crossroads: Sky-High Valuation or Looming Market Correction? - HPBL
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):